Company / SG&A per Share
Corvus Pharmaceuticals, Inc. SG&A per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.13
FY2024
5-year range
$0.13 / $0.40
FY2020-FY2024
Trend
-6.6%
vs FY2023
Sector context
#202 of 208
Health Care
What the data says
Among 208 Health Care companies, Corvus Pharmaceuticals, Inc. is in the top 3% for sg&a per share. SG&A per Share has declined for 4 consecutive years, from $0.40 in FY2020 to $0.13 in FY2024.
Based on SEC 10-K filings.
0.13 in FY2024 with a 5-year CAGR of -18.4%.
Improved from $0.17 to $0.13 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- -16.2%
- 5-Year CAGR
- -18.4%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 208This company $0.13 Sector average $29.78
▼
-99.6% below sector average
Key checks
Key Insights
- Corvus Pharmaceuticals, Inc.'s sg&a per share has declined for 4 consecutive years.
- In FY2024, sg&a per share decreased 6.6% year-over-year.
- Ranks #202 out of 208 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.13 | -6.6% |
| FY2023 | $0.14 | -17.6% |
| FY2022 | $0.17 | -23.5% |
| FY2021 | $0.23 | -43.8% |
| FY2020 | $0.40 | +9.2% |
| FY2019 | $0.37 | -4.1% |
| FY2018 | $0.39 | -22.5% |
| FY2017 | $0.50 | +0.9% |
| FY2016 | $0.49 | -92.4% |
| FY2015 | $6.47 | +795.9% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026